These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 27081697)

  • 1. Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN- 015) for B-Cell malignances.
    Liu X; Wang A; Liang X; Chen C; Liu J; Zhao Z; Wu H; Deng Y; Wang L; Wang B; Wu J; Liu F; Fernandes SM; Adamia S; Stone RM; Galinsky IA; Brown JR; Griffin JD; Zhang S; Loh T; Zhang X; Wang W; Weisberg EL; Liu J; Liu Q
    Oncotarget; 2016 May; 7(22):32641-51. PubMed ID: 27081697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies.
    Liu X; Wang A; Liang X; Liu J; Zou F; Chen C; Zhao Z; Deng Y; Wu H; Qi Z; Wang B; Wang L; Liu F; Xu Y; Wang W; Fernandes SM; Stone RM; Galinsky IA; Brown JR; Loh T; Griffin JD; Zhang S; Weisberg EL; Zhang X; Liu J; Liu Q
    Oncotarget; 2016 Aug; 7(33):53515-53525. PubMed ID: 27447747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.
    Liang X; Li F; Chen C; Jiang Z; Wang A; Liu X; Ge J; Hu Z; Yu K; Wang W; Zou F; Liu Q; Wang B; Wang L; Zhang S; Wang Y; Liu Q; Liu J
    Eur J Med Chem; 2018 Aug; 156():831-846. PubMed ID: 30053721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3K
    Allen RA; Brookings DC; Powell MJ; Delgado J; Shuttleworth LK; Merriman M; Fahy IJ; Tewari R; Silva JP; Healy LJ; Davies GCG; Twomey B; Cutler RM; Kotian A; Crosby A; McCluskey G; Watt GF; Payne A
    J Pharmacol Exp Ther; 2017 Jun; 361(3):429-440. PubMed ID: 28442583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.
    Takeuchi H; Kondo Y; Fujiwara K; Kanzawa T; Aoki H; Mills GB; Kondo S
    Cancer Res; 2005 Apr; 65(8):3336-46. PubMed ID: 15833867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
    Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of single and mixed isoform selectivity PI3Kδ inhibitors by targeting Asn836 of PI3Kδ.
    Miller MS; Mountford SJ; Pinson JA; Zheng Z; Künzli M; Patel V; Hogg SJ; Shortt J; Jennings IG; Thompson PE
    Bioorg Med Chem Lett; 2016 Oct; 26(19):4790-4794. PubMed ID: 27561716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
    Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia.
    Xie C; He Y; Zhen M; Wang Y; Xu Y; Lou L
    Cancer Sci; 2017 Jul; 108(7):1476-1484. PubMed ID: 28418085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors.
    Zhu J; Pan P; Li Y; Wang M; Li D; Cao B; Mao X; Hou T
    Mol Biosyst; 2014 Mar; 10(3):454-66. PubMed ID: 24336903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of highly potent and selective PI3Kδ inhibitors.
    Marcoux D; Qin LY; Ruan Z; Shi Q; Ruan Q; Weigelt C; Qiu H; Schieven G; Hynes J; Bhide R; Poss M; Tino J
    Bioorg Med Chem Lett; 2017 Jul; 27(13):2849-2853. PubMed ID: 28209465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. INCB040093 Is a Novel PI3K
    Shin N; Li YL; Mei S; Wang KH; Hall L; Katiyar K; Wang Q; Yang G; Rumberger B; Leffet L; He X; Rupar M; Bowman K; Favata M; Li J; Liu M; Li Y; Covington M; Koblish H; Soloviev M; Shuey D; Burn T; Diamond S; Fridman J; Combs A; Yao W; Yeleswaram S; Hollis G; Vaddi K; Huber R; Newton R; Scherle P
    J Pharmacol Exp Ther; 2018 Jan; 364(1):120-130. PubMed ID: 29127109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers.
    Young CD; Arteaga CL; Cook RS
    Breast Cancer Res; 2015 Dec; 17():148. PubMed ID: 26637440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent and highly selective benzimidazole inhibitors of PI3-kinase delta.
    Murray JM; Sweeney ZK; Chan BK; Balazs M; Bradley E; Castanedo G; Chabot C; Chantry D; Flagella M; Goldstein DM; Kondru R; Lesnick J; Li J; Lucas MC; Nonomiya J; Pang J; Price S; Salphati L; Safina B; Savy PP; Seward EM; Ultsch M; Sutherlin DP
    J Med Chem; 2012 Sep; 55(17):7686-95. PubMed ID: 22877085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.
    Shingu T; Holmes L; Henry V; Wang Q; Latha K; Gururaj AE; Gibson LA; Doucette T; Lang FF; Rao G; Yuan L; Sulman EP; Farrell NP; Priebe W; Hess KR; Wang YA; Hu J; Bögler O
    J Transl Med; 2016 Feb; 14():46. PubMed ID: 26861698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PI3K/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia.
    Deng L; Jiang L; Lin XH; Tseng KF; Liu Y; Zhang X; Dong RH; Lu ZG; Wang XJ
    Acta Pharmacol Sin; 2017 Mar; 38(3):382-391. PubMed ID: 28042875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth.
    Qin L; Tian Y; Yu Z; Shi D; Wang J; Zhang C; Peng R; Chen X; Liu C; Chen Y; Huang W; Deng W
    Oncotarget; 2016 Jan; 7(2):1395-407. PubMed ID: 26593251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.
    Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Wang NJ; Zhao RJ; Zhou SF
    Drug Des Devel Ther; 2015; 9():487-508. PubMed ID: 25609923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
    Li H; Jin X; Zhang Z; Xing Y; Kong X
    Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells.
    Goulielmaki M; Koustas E; Moysidou E; Vlassi M; Sasazuki T; Shirasawa S; Zografos G; Oikonomou E; Pintzas A
    Oncotarget; 2016 Feb; 7(8):9188-221. PubMed ID: 26802026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.